of Health, Education, and Welfare conducted a telephone survey of 331 investigators to determine the incidence of research-related injuries. In this survey of 93 399 subjects, there were 711 (0.8 percent) reported injuries, of which 94.7 percent were classified as trivial, 5.2 percent as temporarily disabling, < 0.1 percent as permanently disabling, and no fatalities.' Two years later, Zarafonetis et at. summarized their 12-year experience with phase I drug testing in normal prison volunteers. Of 29 162 subjects studied, they encountered 64 (0.2 percent) clinically significant adverse drug effects and complications. Using the same criteria as the HEW report, 64 (93.8 percent) were temporarily disabling, I (3.1 percent) permanently disabling, and there was 1 (3.1 percent) fatality due to a cerebrovascular hemorrhage in a subject on placebo. These adverse effects were most frequently of an allergic, cardiovascular, or neurologic nature." Together, these studies provide a sense of acceptable safety and limited risk.
More recently, there are several case reports of death in healthy or apparently healthy volunteers who were participating in drug studies.v" Unbeknownst to the investigators, one of these subjects had anorexia nervosa' and another had been receiving a neuroleptic drug." These factors were felt to have been significant in contributing to the subject's death. The reports are sobering and should be required reading for anyone engaged in this type of research.
One is left with the most important question for future research subjects: could these deaths have been prevented? The reports do not offer much hope that they could have been prevented. One procedure now required by some drug companies is a urine drug screen.
While this may help, drug screens do not detect all possible drugs, nor do they prevent a subject from taking other drugs after a study has begun. Investigators might ask themselves several questions. Do some studies pay subjects so much that they are willing to give inaccurate histories? Are you so busy that you do not actually participate in screening subjects or in conducting the study? Is the study conducted in an environment and with appropriate medical supervision to respond to a medical emergency? Should the research question be asked in the population for which the drug is intended? Is the research question asked either trivial or predictable in outcome? Have you made adequate provisions to cover the medical expensesof the subject and liability expenses for yourself?
Drug research conducted in healthy volunteers has a small but real and potentially catastrophic risk. While a primary tenet of medicine is "do no harm," it should be modified in this situation to "especially do no harm to healthy people."
